Pharmafile Logo

twindemic

- PMLiVE

Gilead strikes deal with NHS England on CAR-T Yescarta

NHS England claims adult leukaemia access is first in Europe

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

Novartis’ CAR-T Kymriah gets green light in England

Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population

Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination

Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...

Research Partnership

- PMLiVE

Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

Public row about confidential pricing talks drags on

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

- PMLiVE

Daily Brief: GDPR and NHS Opt Out Day, BioMarin’s new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

- PMLiVE

NHS seeks ‘solution creators’ from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

To track disease, follow the money

Using paper currency to track infections sounds like a clever idea. But we think the smart money is on your phone.

Life Healthcare Communications

- PMLiVE

Judge forces NHS England rethink on Kuvan

The health service claims the drug is not clinically effective

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links